Business
Medicenna Announces Presentation at the 2017 Innovations In Cancer Prevention and Research Conference
Medicenna Announces Presentation at the 2017 Innovations In Cancer Prevention and Research...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Announces Presentation at the 2017 Innovations In Cancer Prevention and Research Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; BORDER-LEFT:black 0pt; PADDING-LEFT:0.50em; PADDING-RIGHT:0.50em; VERTICAL-ALIGN: TOP; BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, TX, Oct. 31, 2017\n\n\n\n\n\n\n\nTORONTO and HOUSTON, TX, Oct. 31, 2017 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSX: MDNA; OTCQX: MDNAF), a clinical stage immuno-oncology company, today announced that Dr. Martin Bexon, MD, Head of Clinical Development at Medicenna, will present results from earlier clinical trials at the Cancer Prevention and Research Institute of Texas' (\"CPRIT\") Fifth Innovations in Cancer Prevention and Research Conference to be held from November 13-14, 2017 in Austin, TX.  \n\nThe poster presentation by Dr. Bexon will provide an overview of the safety and efficacy results from previous Phase 1 and 2 clinical trials of the targeted immunotherapy, MDNA55, in 66 patients with recurrent glioblastoma (rGBM), the most common and deadly form of brain cancer. \n\nThe details of the presentation are as follows:\n\n\n\n\nTitle:         \n\n\nClinical Safety and Efficacy of MDNA55: Results of 3 Studies in Recurrent Malignant Gliomas\n\n\n\nDate:       \n\n\nTuesday, November 14, 2017\n\n\n\nTime:         \n\n\n10:00 AM\n\n\n\nSession:      \n\n\nTreatment and Therapeutics\n\n\n\nSession ID:  \n\n\nPoster Group B\n\n\n\nLocation:    \n\n\nRenaissance Arboretum Hotel, Austin, TX\n\n \n\nAbout Medicenna Therapeutics Corp. \n\nMedicenna is a clinical stage immuno-oncology company developing novel highly select...